Int. Appln. No.: PCT/CA2004/000833

US Appln. No.: To be Assigned US Filing Date: Concurrently

Case No.: MC083P Page No.: 3

## Amendment to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. (original) A compound of formula I:

$$Z^{3}$$
 $Z^{4}$ 
 $Z^{1}$ 
 $Z^{2}$ 
 $Z^{1}$ 
 $Z^{1}$ 
 $Z^{2}$ 
 $Z^{1}$ 
 $Z^{1$ 

and pharmaceutically acceptable salts and hydrates thereof, wherein:

Ar is aryl or heteroaryl each optionally substituted with one to four groups independently selected from Rg;

Q is -A-Q';

A is selected from (1)  $C_{1-3}$ alkyl optionally substituted with one to four halogen atoms or with one to two  $CF_3$  groups, (2)  $O(CH_2)_{1-2}$ , and (3)  $S(O)_n(CH_2)_{1-2}$ ;

Q' is selected from COOH, CONR<sup>a</sup>R<sup>b</sup>, C(O)NHSO<sub>2</sub>R<sup>c</sup>, SO<sub>2</sub>NHR<sup>a</sup>, SO<sub>3</sub>H, PO<sub>3</sub>H<sub>2</sub>, and tetrazolyl;

one of  $Z^1$ ,  $Z^2$ ,  $Z^3$  or  $Z^4$  is N or N $\rightarrow$ O, and the others are independently selected from CH and C-Rg;

X is selected from -(CRdRe)<sub>a</sub>-W-(CRdRe)<sub>b</sub>-, phenylene, C<sub>3-6</sub>cycloalkylidene and

C3-6cycloalkylene, wherein a and b are integers 0-1 such that the sum of a and b equals 0, 1 or 2, and W is a bond,  $-SO_2$ , -C(O)-, -C(O)O-, -C(O)O-, -C(O)NRa-, -CRd=-CRe- or -C=-C-;

 $R^1$  is selected from H, CN,  $OR^a$ ,  $-S(O)_nC_{1-6}$ alkyl and  $C_{1-6}$ alkyl optionally substituted with one to six groups independently selected from halogen,  $OR^a$  and  $-S(O)_nC_{1-6}$ alkyl;

R<sup>2</sup> is H or C<sub>1-6</sub>alkyl optionally substituted with one to six halogen; or

 $R^1$  and  $R^2$  together represent an oxo; or

Int. Appln. No.: PCT/CA2004/000833 US Appln. No.: To be Assigned US Filing Date: Concurrently

Case No.: MC083P Page No.: 4

 $R^1$ ,  $R^2$  and the atom(s) to which they are attached taken together form a 3- or 4- membered ring containing 0 or 1 heteroatom selected from  $NR^f$ , S, and O optionally substituted with one or two groups selected from F, CF3 and CH3;

R<sup>3</sup> is H or C<sub>1-6</sub>alkyl optionally substituted with one to six groups independently selected from - OR<sup>a</sup> and halogen;

R<sup>a</sup> and R<sup>b</sup> are independently selected from H, C<sub>1-10</sub>alkyl, C<sub>2-10</sub>alkenyl, C<sub>2-10</sub>alkynyl, Cy and Cy-C<sub>1-10</sub>alkyl-, wherein said alkyl, alkenyl, alkynyl and Cy are optionally substituted with one to six substituents independently selected from halogen, amino, carboxy, C<sub>1-4</sub>alkyl, OH, C<sub>1-4</sub>alkoxy, aryl, heteroaryl, aryl-C<sub>1-4</sub>alkyl-, hydroxy, CF<sub>3</sub>, -OC(O)C<sub>1-4</sub>alkyl, -OC(O)NR<sup>i</sup>R<sup>j</sup>, and aryloxy; or

Ra and Rb together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rf;

R<sup>c</sup> is selected from C<sub>1-6</sub>alkyl optionally substituted with one to six halogen, aryl and heteroaryl, wherein said aryl and heteroaryl are optionally substituted with halogen, -OC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl and wherein said alkyl is optionally substituted with one to six halogen;

Rd and Re are independently H, halogen, aryl, heteroaryl, C<sub>1-6</sub>alkyl or haloC<sub>1-6</sub>alkyl;

 $R^f$  is selected from H,  $C_{1-6}$ alkyl, halo $C_{1-6}$ alkyl,  $C_{1-6}$ alkyl, - $C_{1-6}$ alkyl, - $C_{1-6}$ alkyl, and - $C_{1-6}$ alkyl, halo $C_{1-6}$ alkyl, halo $C_{1-6}$ alkyl, and - $C_{1-6}$ alkyl, halo $C_{1-6}$ alkyl, halo $C_{1-6}$ alkyl, halo $C_{1-6}$ alkyl, and - $C_{1-6}$ alkyl, halo $C_{1-$ 

Rg is selected from (1) halogen, (2) CN, (3) C<sub>1</sub>-6alkyl optionally substituted with one to eight groups independently selected from aryl, heteroaryl, halogen, NRaRb, C(O)Ra, C(ORa)RaRb, SRa and ORa, wherein aryl, heteroaryl and alkyl are each optionally substituted with one to six groups independently selected from halogen, CF<sub>3</sub>, and COOH, (4) C<sub>2</sub>-6alkenyl optionally substituted with one to six groups independently selected from halogen and ORa, (5) Cy, (6) C(O)Ra, (7) C(O)ORa, (8) CONRaRb, (9) OCONRaRb, (10) ORa, (11) SH, (12) -S(O)nC<sub>1</sub>-6alkyl, wherein alkyl is optionally substituted with one to six substituents selected from halogen, aryl, heteroaryl, OH, and OC(O)Ra, (13) -S(O)naryl, (14) -S(O)nheteroaryl, (15) -NRaS(O)nRb, (16) -NRaRb, (17) -NRaC(O)Rb, (18) -NRaC(O)ORb, (19) -NRaC(O)NRaRb, (20) - S(O)nNRaRb, (21) NO<sub>2</sub>, (22) C<sub>5</sub>-8cycloalkenyl; wherein Cy is optionally substituted with one to

Int. Appln. No.: PCT/CA2004/000833 US Appln. No.: To be Assigned

US Filing Date: Concurrently

Case No.: MC083P

Page No.: 5

eight groups independently selected from halogen, C(O)Ra, ORa, C<sub>1</sub>-3alkyl, aryl, heteroaryl and CF<sub>3</sub>;

R<sup>i</sup> and R<sup>j</sup> are independently selected from hydrogen, C<sub>1-10</sub>alkyl, Cy and Cy-C<sub>1-10</sub>alkyl-; or R<sup>i</sup> and R<sup>j</sup> together with the nitrogen atom to which they are attached form a ring of 5 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R<sup>f</sup>;

Cy is selected from heterocyclyl, aryl, and heteroaryl; m is 1, 2 or 3; and n is 0, 1 or 2.

- 2. (original) A compound of Claim 1 wherin Q is CH2CO2H.
- 3. (original) A compound of Claim 1 wherein X-Ar is  $-(CR^dR^e)_a$ - $(CR^dR^e)_b$ -aryl, -SO2-aryl or -C(O)-aryl, wherein said aryl is naphthyl or phenyl optionally substituted with 1 to 2 groups selected from Rg.
- 4. (original) A compound of Claim 1 wherein X-Ar is benzyl or  $\alpha$ -methylbenzyl wherein the phenyl moiety is substituted with one to three chlorine atoms.
- 5. (original) A compound of Claim 1 wherein  $Z^3$  is nitrogen and  $Z^1$ ,  $Z^2$  and  $Z^4$  are independently selected from CH and CRg.
- 6. (original) A compound of Claim 1 wherein  $Z^3$  is nitrogen and one of  $Z^1, Z^2$  and  $Z^4$  is CRg and the others are CH.
- 7. (original) A compound of Claim 1 wherein  $Z^3$  is nitrogen,  $Z^1$  is C-SO<sub>2</sub>-C<sub>1-3alkyl</sub>,  $Z^2$  and  $Z^4$  are each CH.
  - 8. (original) A compound of Claim 1 wherein m is 1 or 2.

Int. Appln. No.: PCT/CA2004/000833

US Appln. No.: To be Assigned US Filing Date: Concurrently

Case No.: MC083P Page No.: 6

9. (original) A compound of Claim 1 wherein  $R^1$ ,  $R^2$  and  $R^3$  are each hydrogen, or  $R^1$  and  $R^2$  together is oxo, and  $R^3$  is hydrogen.

## 10. (original) A compound of Claim 1 having the formula Ia:

wherein Ar, Q, X, Z<sup>1</sup>, Z<sup>2</sup>, Z<sup>4</sup>, R<sup>1</sup>, R<sup>2</sup> and m are as defined in Claim 1.

- 11. (original) A compound of Claim 10 wherein Q is CH2CO2H.
- 12. (original) A compound of Claim 10 wherein X is CH2 or CH(CH3).
- 13. (original) A compound of Claim 10 wherein Ar is phenyl optionally substituted with one to three groups selected from Rg.
- 14. (original) A compound of Claim 10 wherein Ar is phenyl optionally substituted with one to three halogen atoms.
  - 15. (original) A compound of Claim 10 wherein Z<sup>2</sup> and Z<sup>4</sup> are each CH.
  - 16. (original) A compound of Claim 1 having the formula Ib:

Int. Appln. No.: PCT/CA2004/000833 US Appln. No.: To be Assigned

US Filing Date: Concurrently

Case No.: MC083P

Page No.: 7

$$CO_2H$$
 $CO_2H$ 
 $CO_2H$ 
 $CO_2H$ 

wherein  $Z^1$  and m are as defined in Claim 1; Ar is phenyl optionally substituted with one or two Rg groups, and X is CH<sub>2</sub> or CH(CH<sub>3</sub>).

- 17. (original) A compound of Claim 16 wherein Z<sup>1</sup> is C-SO<sub>2</sub>-C<sub>1-3</sub>alkyl.
- 18. (original) A compound of Claim 16 wherein Ar is phenyl substituted with one or two halogen atoms.
- 19. (original) A compound of Claim 16 wherein  $Z^1$  is C-SO<sub>2</sub>-C<sub>1-3</sub>alkyl and Ar is phenyl substituted with one or two halogen atoms.
- 20. (original) A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.
- 21. (original) The composition of Claim 20 further comprising a second active ingredient selected from an antihistamine, a leukotriene antagonist and a leukotriene biosynthesis inhibitor.
- 22. (original) A method for the treatment of prostaglandin D2 mediated diseases or conditions which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of Claim 1.

Int. Appln. No.: PCT/CA2004/000833

US Appln. No.: To be Assigned US Filing Date: Concurrently

Case No.: MC083P

Page No.: 8

23. (original) A method of Claim 22 wherein said prostaglandin D2 mediated disease or condition is selected from nasal congestion, allergic rhinitis, asthma and flushing induced by niacin.

- 24. (canceled).
- 25. (canceled).
- 26. (canceled).
- 27. (canceled).